ArticleCancer discovery2020
Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 2 pooled it
7.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 2 syntheses or guidelines pooled it, 141 citations in OpenAlex.
- NK cell adoptive transfer in acute myeloid leukemia: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- A systematic review of the last two decades of NK cell-based clinical trials: state of the art of AML therapy.BMC cancer · 2025Pooled it
- Trial
- Next-generation natural killer cell therapy: bench to bedside and beyond.Signal transduction and targeted therapy · 2026Review
- Cytokine-induced expandable memory NK cells with significant metabolic, epigenetic remodeling, and persistence properties.Cell death discovery · 2026Article
- Immunotherapy in acute myeloid leukemia: The antibodies, TriKEs, and CARs on the arduous road to cure.Blood reviews · 2026Review
- Transcriptional Profile Change of NK-92 Cells in Presence of Cytokines, TGFβ Signaling Pathway Inhibitor and CDK7/12/13 Kinase Inhibitor.International journal of molecular sciences · 2026Article
- Pumping up immunity: exercise flexes memory NK cell attack.Blood advances · 2026Article
- Exercise-mobilized lymphocytes enhance the function of cytokine-induced memory-like NK cells against myeloid leukemia.Blood advances · 2026Article
- Natural killer cells: gatekeepers of healthy aging in longevity medicine.Inflammation and regeneration · 2026Review
- HOPX is required for the generation of umbilical cord blood-derived memory-like NK cells induced by three cytokines.Frontiers in immunology · 2026Article
- Engineered natural killer cells for cancer therapy.Cancer cell · 2025Review
- The role of NK cells in regulating tumorimmunity: current state, challenges and future strategies.Cancer cell international · 2025Review
- Analysis of Phenotypic and Molecular Variability of Memory-like NK Cells for Cancer Adoptive Cell Therapy Screening.Cancers · 2025Article
- Natural killer cell-based immunotherapy for cancer.Journal of immunology (Baltimore, Md. : 1950) · 2025Review
- NKG2D ligand expression on NK cells induces NKG2D-mediated cross-tolerization of cytokine signaling and reduces NK cell tumor immunity.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Single-cell transcriptomic profiling reveals diversity in human iNKT cells across hematologic tissues.Cell reports · 2025Article
- Emerging Role of Chimeric Antigen Receptor-Natural Killer Cells for the Treatment of Hematologic Malignancies.Cancers · 2025Review
- Engineering innate immune cells for cancer immunotherapy.Nature biotechnology · 2025Review
- First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 1 institution in 1 country.
Melissa M Berrien-ElliottDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri. tfehnige@wustl.edu melissa.berrien@wustl.edu.ORCID https://orcid.org/0000-0002-7319-9159
Amanda F CashenDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Celia C CubittDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID https://orcid.org/0000-0003-0037-9324
Carly C NealDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Pamela WongDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID https://orcid.org/0000-0002-6856-2603
Julia A WagnerDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Mark FosterDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Timothy SchappeDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Sweta DesaiDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Ethan McClainDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Michelle Becker-HapakDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Jennifer A FoltzDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID https://orcid.org/0000-0001-9158-3464
Matthew L CooperDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Natalia JaegerDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Sridhar Nonavinkere SrivatsanDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Feng GaoSiteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri.
Rizwan RomeeDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Camille N AbboudDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Geoffrey L UyDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID https://orcid.org/0000-0002-7809-0996
Peter WesterveltDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Meagan A JacobyDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Iskra PusicDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Keith E Stockerl-GoldsteinDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID https://orcid.org/0000-0002-7234-1715
Mark A SchroederDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID https://orcid.org/0000-0003-4924-8990
John DiPersioDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Todd A FehnigerDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri. tfehnige@wustl.edu melissa.berrien@wustl.edu.
Washington University in St. Louis · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0MWU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8MNATIONAL RESEARCH SERVICE AWARD-MEDICAL SCIENTISTT32GM007200 · NIGMS · WASHINGTON UNIVERSITY · PI YOKOYAMA, WAYNE M. · 1985 to 2024
$59.8MTargeting the Bone Marrow Microenvironment In Acute Lymphocytic LeukemiaP50CA171963 · NCI · WASHINGTON UNIVERSITY · PI Daniel C Link · 2013 to 2026
$31.6MPRE-AND POSTGRADUATE TRAINING IN MOLECULAR HEMATOLOGYT32HL007088 · NHLBI · WASHINGTON UNIVERSITY · PI Grant Anthony Challen, Stephen Oh · 1985 to 2026
$14.1MWashington University Paul Calabresi K12 Career Development Award for Clinical OncologyK12CA167540 · NCI · WASHINGTON UNIVERSITY · PI John F. Dipersio, Ramaswamy Govindan · 2012 to 2026
$11.7MTRANSLATING NK CELL BIOLOGY INTO CLINICAL CANCER IMMUNOTHERAPYR01CA205239 · NCI · WASHINGTON UNIVERSITY · PI FEHNIGER, TODD A · 2017 to 2020
$2.4MMechanisms underlying cytokine-induced memory-like natural killer cell differentiation and maintenance.F32CA200253 · NCI · WASHINGTON UNIVERSITY · PI ELLIOTT, MELISSA BERRIEN · 2015 to 2017
$168kNCATS NIH HHS UL1 TR002345NCI NIH HHS F32 CA200253NCI NIH HHS K12 CA167540NCI NIH HHS P30 CA091842NCI NIH HHS P50 CA171963NCI NIH HHS R01 CA205239NHLBI NIH HHS T32 HL007088NIGMS NIH HHS T32 GM007200
Abstract
Natural killer (NK) cells are an emerging cancer cellular therapy and potent mediators of antitumor immunity. Cytokine-induced memory-like (ML) NK cellular therapy is safe and induces remissions in patients with acute myeloid leukemia (AML). However, the dynamic changes in phenotype that occur after NK-cell transfer that affect patient outcomes remain unclear. Here, we report comprehensive multidimensional correlates from ML NK cell-treated patients with AML using mass cytometry. These data identify a unique
Indexed as
HumansImmunotherapy, AdoptiveKiller Cells, NaturalLeukemia, Myeloid, Acute
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.